某地区支气管扩张症患者感染黏液型铜绿假单胞菌的耐药分析

Drug resistance and its analysis of mucoid Pseudomonas aeruginosa infection in patients with bronchiectasis in an area

目的 分析本地区支气管扩张症患者感染黏液型铜绿假单胞菌的药敏情况,为临床治疗提供参考。方法 对2018年—2021年本地区患者分离的黏液型铜绿假单胞菌耐药性进行回顾性分析。结果 支气管扩张症患者感染mPA组反复感染率高于非mPA组(P<0.05)。本地区分离的40株mPA对阿米卡星、头孢哌酮/他唑巴坦敏感率> 90%,而左旋氧氟沙星、环丙沙星耐药率相对较高。追踪24例感染mPA的支扩患者显示初次检出与治疗3个月后、6个月后、9个月后、12个月后对常见抗生素耐药率的变化差异均无统计学意义(P> 0.05),其用药方案多使用联合用药。结论 支气管扩张症伴黏液型铜绿假单胞菌感染的患者,临床治疗时在选择敏感抗生素基础上应添加大环内酯类药物以破坏生物被膜,来提高抗菌治疗效果。

Objective To analyze the drug resistance of mucoidPseudomonas aeruginosainfection in patients with bronchiectasis in Pinghu area,so as to provide reference for the clinical treatment.Methods A retrospective analysis was performed on the drug resistance of mucoidPseudomonas aeruginosain patients with bronchiectasis isolated during 2018—2021.Results The rate of recurrent infections was higher in the mPA group than that in the non-mPA group in patients with bronchiectasis(P 0.05),and the drug regimen was mostly combination drug.Conclusion In patients with bronchiectasis with mucoidPseudomonas aeruginosainfection,clinical treatment is recommended to add macrolides to disrupt the biofilm based on the selection of sensitive antibiotics to improve the effectiveness of antibacterial therapy.